Allergan, Inc. Announces Appointment of Douglas S. Ingram as President

  Allergan, Inc. Announces Appointment of Douglas S. Ingram as President

 -Ingram to Assume Responsibility for Allergan Global Commercial Operations-

 -Previously Served as Executive Vice President and President Europe, Africa,
                               and Middle East-

Business Wire

IRVINE, Calif. -- June 24, 2013

Allergan, Inc. (NYSE:AGN) today announced that David E.I. Pyott, Chairman of
the Board and Chief Executive Officer, Allergan, and the Allegan Board of
Directors have named Douglas S. Ingram as President of Allergan. In this newly
established role, Mr. Ingram will report directly to Mr. Pyott and will lead
the company’s global commercial operations, with responsibility for the
company’s broad portfolio of pharmaceutical, consumer and medical device
products including leading Ophthalmology products such as RESTASIS^®,
Aesthetics products such as BOTOX^® Cosmetic and the JUVÉDERM^® family of
facial fillers; BOTOX^® for therapeutic uses, approved in over 85 countries to
treat 26 different conditions such as spasticities, dystonias, chronic
migraine and the urological conditions of neurogenic detrusor overactivity and
idiopathic overactive bladder; and Medical Dermatology products such as
ACZONE^®. Mr. Ingram will begin transitioning to this new role immediately.

“During his 17-year tenure at Allergan, Doug has consistently demonstrated
leadership and high performance across many segments of our business,” said
David E.I. Pyott, Chairman of the Board and Chief Executive Officer, Allergan.
“Doug has built an impressive record of accomplishment and is widely regarded
throughout our organization as a leader who is committed to the highest
standards of excellence in all areas. I am confident that his broad range of
commercial and functional experiences will serve him well as he assumes this
new and important role.”

With more than 25 years of professional experience, Mr. Ingram has a strong
background in the health care industry, both in the U.S. and internationally.
For the past three years, Mr. Ingram has served as Executive Vice President
and President, Europe, Africa and Middle East (EAME). In this role, he was
responsible for Allergan’s regional pharmaceutical and medical device
operations, with a focus on strategic planning, sales and marketing,
development and general management.

Prior to leading the EAME region, Mr. Ingram served as Executive Vice
President and Chief Administrative Officer. During Mr. Ingram’s tenure in this
role, at various times, he led Allergan’s Global Legal Affairs, Compliance,
Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and
Safety, and Global Corporate Affairs and Public Relations departments. Mr.
Ingram also served as Allergan’s Secretary and Chief Ethics Officer from July
2001 to July 2010. Mr. Ingram joined Allergan in 1996 as Senior Attorney and
Chief Litigation Officer and was promoted to Associate General Counsel and
Assistant Secretary, and later, to General Counsel.

Before joining Allergan in 1996, Mr. Ingram was an attorney with Gibson, Dunn
& Crutcher from 1988, practicing in the area of complex commercial litigation.

Mr. Ingram graduated magna cum laude with a Bachelor of Science degree from
Arizona State University in 1985 and received his  Juris Doctorate from the
University of Arizona in 1988, graduating summa cum laude and Order of the

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life’s
potential. Today, we have approximately 11,100 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and physicians who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go to:

Forward-Looking Statements

This press release contains “forward-looking statements,” including the
statements by Mr. Pyott. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
Allergan’s expectations and projections. Risks and uncertainties include,
among other things, general industry and pharmaceutical market conditions;
challenges related to achieving regulatory approval from the FDA on a timely
and cost-efficient manner; technological advances and patents attained by
competitors and the impact of generic competition; inconsistency of treatment
results among patients; potential difficulties in manufacturing; challenges
related to new product marketing, such as the unpredictability or market
acceptance for new products and/or the acceptance of new indications for such
products; the outcome of litigation or any other legal or government
proceeding; and governmental laws and regulations affecting domestic and
foreign operations. Allergan expressly disclaims any intent or obligation to
update these forward-looking statements except as required by law. Additional
information concerning these and other risks can be found in press releases
issued by Allergan, as well as Allergan’s public filings with the U.S.
Securities and Exchange Commission, including the discussion under the heading
“Risk Factors” in Allergan’s most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q. Copies of Allergan’s press releases
and additional information about Allergan are available at or
you can contact the Allergan Investor Relations Department by calling

^©2013 Allergan, Inc. Irvine, CA 92612. ^® and ^™ marks owned by Allergan,


Allergan Contacts:
Bonnie Jacobs (714) 246-5134 (media),
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)
David Nakasone (714) 246-6376 (investors)
Press spacebar to pause and continue. Press esc to stop.